Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GS-0201 by Gilead Sciences for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
GS-0201 by Gilead Sciences for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
GS-0201 by Gilead Sciences for Solid Tumor: Likelihood of Approval
GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...